Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
Henry M. Jackson Foundation for the Advancement of Military Medicine · with Centers for Disease Control and Prevention, Food and Drug Administration (FDA) · NCT07287137
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–79 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 4
- Target enrollment
- 54
- US sites recruiting
- 1
- Study start
- November 12, 2025
- Record last updated
- October 28, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2026 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.
Being studied: Pfizer-BioNTech mRNA COVID-19 vaccine; Novavax recombinant protein vaccine
Conditions: COVID -19; COVID - 19; COVID 19; Influenza; Respiratory Virus; Respiratory Viruses; Respiratory Virus Infection; Respiratory Virus Infections
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- 18-79 years old
- Have a history of any of the following risk factors for severe COVID:
Current
- Age > 65 years old
- Physical inactivity (defined as \<150 mins of moderate activity per week or \<75 mins of vigorous activity per week)
- HIV with CD4 count ≥ 500 cells/ul
- Smoker
- Obesity with BMI ≥ 30 and \< 40
History of
- Asthma
- Depression or other mood disorder
- Schizophrenia spectrum disorder
- Cerebrovascular disease
- Heart failure
- Coronary artery disease
- Cardiomyopathy
- Pulmonary embolism
- Pulmonary hypertension
- Cystic fibrosis
- Bronchiectasis
- Chronic obstructive pulmonary disease
- Interstitial Lung Disease
- Stage I or II chronic kidney disease (Stage 1 defined as normal GFR (> 90) but with other signs of kidney damage such as proteinuria or hematuria) (Stage 2 defined as having a glomerular filtration rate (GFR) of 60 - 89 ml/min/1.73m2)
- Gestational diabetes
- Type 1 diabetes with most recent HgbA1C \< 7.5%
- Type 2 diabetes with most recent HgbA1C \< 7.5%
- Liver disease without cirrhosis and with liver enzyme levels (AST and ALT) no greater than three times the upper limit of normal
- Smoking
- Military Health System beneficiary and DEERS eligible
- Willing to be randomized to receive either the Novavax COVID-19 vaccine or the mRNA Pfizer-BioNTech COVID-19 vaccine
- Will be able to return for a clinic visit in approximately 30 days, Day 150, and be able to follow-up online for the next 9 months.
Exclusion Criteria
- History of severe allergy or severe adverse reaction such as myocardial inflammation to any component of the mRNA COVID-19 vaccines or the Novavax recombinant COVID-19 vaccine
- Received a COVID-19 vaccine in the last 3 months.
- Tested positive for COVID-19 in the past 3 months.
- Presence of fever, cough, chills, shortness of breath, runny nose, or sore throat today on day of screening/enrollment visit.
- Active use of immune modulating medications.
- Defined as active use of chronic immune modulating medications such as systemic corticosteroids at a dose equivalence of 20 mg prednisone or greater daily for over one month, chemotherapy, cytokine inhibitors, or agents that reduce T cell or B cell numbers or function.
- Diagnosed with immunocompromised stated.
- Defined as: presence of a disease that is actively causing severe immune suppression or history of prior splenectomy (removal of spleen).
- Diabetes with the most recent HgbA1C ≥ 7.5.
- Stage III or greater chronic kidney disease
- Defined as estimated glomerular filtration rate \< 60 ml/min/1.73m2)
- Obesity with a BMI ≥ 40
- HIV with a CD4 cell count \< 500 cells/ul
- History of solid organ or bone marrow transplant.
- Active malignancy
- Defined as any cancer that is currently being treated or has shown evidence of progression within the past year.
- Chronic liver disease with compensated or decompensated cirrhosis, or liver enzyme levels (AST or ALT) greater than three times the upper limit of normal.
Recruiting US locations
Walter Reed National Military Medical Center
Bethesda, MD 20814
Site contact: Irma Barahona · 301-319-8673 · irma.l.barahona.ctr@health.mil
Study contacts (from the official record)
- Marianne Spevak, BSHS · 240-694-2067 · mspevak@hjf.org
Similar studies in Maryland
All vaccine studies in Maryland →- RecruitingHealthy volunteersPhase 1
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Merck Sharp & Dohme LLC
- Location
- Columbia, MD + 14 other US sites
- Eligibility basics
- Ages 2 mo–1
- RecruitingHealthy volunteersPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
National Institute of Allergy and Infectious Diseases (NIAID)
- Location
- Baltimore, MD + 4 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingHealthy volunteersPhase 1/Phase 2
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
National Institute of Allergy and Infectious Diseases (NIAID)
- Location
- Bethesda, MD
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
National Institute of Allergy and Infectious Diseases (NIAID)
- Location
- Bethesda, MD
- Eligibility basics
- Ages 18–29